专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140135483A1 SOLUBLE INTEGRIN ALPHA-4 MUTANT 审中-公开
标题翻译：可溶性INTEGRIN ALPHA-4突变体
公开(公告)号：US20140135483A1
公开(公告)日：2014-05-15
申请号：US14129817
申请日：2012-06-28
申请人： Tsutomu Seito , Shigeyuki Kon
发明人： Tsutomu Seito , Shigeyuki Kon
IPC分类号： C07K14/705 , C07K16/28
CPC分类号： C07K14/70546 , A61K38/00 , A61K39/0007 , A61K2039/55566 , A61K2039/6031 , C07K14/71 , C07K16/2839 , C07K2317/34
摘要： The present invention addresses the problem of providing a novel substance capable of interfering with various functions of integrin α4, and/or providing a novel substance capable of interfering with both integrin α4 and integrin α9. The present invention provides an integrin α4 mutant peptide having one portion of the extracellular domain of human integrin α4, and the like, and in concrete terms relates to a peptide and the like having the amino acid sequence of Sequence No. 4 through 9, and a pharmaceutical composition comprising as the active ingredient the same peptide.
摘要翻译：本发明解决提供能够干扰整联蛋白α4的各种功能的新物质和/或提供能够干扰整联蛋白α4和整联蛋白α9的新型物质的问题。本发明提供了具有人整联蛋白α4的细胞外结构域的一部分的整联蛋白α4突变体肽等，具体而言涉及具有序列号4〜9的氨基酸序列的肽等，作为活性成分含有相同肽的药物组合物。

2. 发明授权

US08617829B2 Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof 有权
公开(公告)号：US08617829B2
公开(公告)日：2013-12-31
申请号：US13497692
申请日：2010-09-22
申请人： Shankar Kumar , J. Yun Tso , Naoya Tsurushita
发明人： Shankar Kumar , J. Yun Tso , Naoya Tsurushita
IPC分类号： C12Q1/68 , C07K16/00 , C07K16/46 , C07K16/24
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

3. 发明授权

US08372639B2 Anti-human α9 integrin antibody and use thereof 有权
公开(公告)号：US08372639B2
公开(公告)日：2013-02-12
申请号：US13138470
申请日：2009-02-23
申请人： Shigeyuki Kon , Toshimitsu Uede
发明人： Shigeyuki Kon , Toshimitsu Uede
IPC分类号： C12N5/20 , C07K16/00 , C07K16/46 , C07K16/28
CPC分类号： C07K16/2839 , C07K2317/76 , G01N2333/70546
摘要： The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin.

4. 发明申请

US20110092575A1 SIRNA OF HUMAN OSTEOPONTIN 审中-公开
标题翻译：人类骨质疏松症SIRNA
公开(公告)号：US20110092575A1
公开(公告)日：2011-04-21
申请号：US12737040
申请日：2008-06-06
申请人： Toshimitsu Uede
发明人： Toshimitsu Uede
IPC分类号： A61K31/713 , C07H21/02 , C12N15/63 , A61K31/7105 , A61P35/00 , A61P9/10 , A61P19/02 , A61P1/16
CPC分类号： C12N15/113 , A61K31/713 , C07K14/52 , C12N2310/14
摘要： The present invention provides siRNA for suppressing expression of human osteopontin in a more specific and strong manner, and a composition and a medicine comprising the same.
摘要翻译：本发明提供了以更具体和更强的方式抑制人骨桥蛋白表达的siRNA，以及包含其的组合物和药物。

5. 发明授权

US08735552B2 Generation, expression and characterization of the humanized K33N monoclonal antibody 有权
标题翻译：人源化K33N单克隆抗体的产生，表达和表征
公开(公告)号：US08735552B2
公开(公告)日：2014-05-27
申请号：US13201847
申请日：2010-03-10
申请人： Shankar Kumar , J. Yun Tso , Naoya Tsurushita , Tatsuhiro Harada
发明人： Shankar Kumar , J. Yun Tso , Naoya Tsurushita , Tatsuhiro Harada
IPC分类号： C07K16/28
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/6887
摘要： The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
摘要翻译：本发明提供免疫特异性识别人9整联蛋白的人源化抗体。这些抗体中的一些抑制9整联蛋白的生物学功能，从而对与9种整合素（包括癌症）相关的各种疾病或疾病表现出治疗效果，例如癌细胞的生长和转移，以及炎性疾病，例如类风湿关节炎，骨关节炎，肝炎，支气管哮喘，纤维化，糖尿病，动脉硬化，多发性硬化，肉芽肿，炎性肠病（溃疡性结肠炎和克罗恩病），自身免疫性疾病等。

6. 发明授权

US08614296B2 Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof 有权
标题翻译：细胞外基质蛋白的氨基酸序列RGD特异的人源化抗体及其用途
公开(公告)号：US08614296B2
公开(公告)日：2013-12-24
申请号：US12989208
申请日：2009-04-24
申请人： Shankar Kumar , J. Yun Tso , Naoya Tsurushita , Shigeyuki Kon , Toshimitsu Uede
发明人： Shankar Kumar , J. Yun Tso , Naoya Tsurushita , Shigeyuki Kon , Toshimitsu Uede
IPC分类号： C07K16/00 , C07K16/46 , C07K16/28
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/30 , C07K2317/24
摘要： The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
摘要翻译：本发明提供免疫特异性识别RGD序列的人源化抗体。这些抗体中的一些抑制RGD蛋白的生物学功能，从而对与RGD蛋白相关的各种疾病或疾病表现出治疗效果，包括癌症，例如癌细胞的生长和转移，以及炎性疾病，例如类风湿关节炎，骨关节炎，肝炎，子宫内膜异位症，支气管哮喘，纤维化，糖尿病，动脉硬化，多发性硬化，肉芽肿，炎性肠病（溃疡性结肠炎和克罗恩病），自身免疫性疾病等。

7. 发明授权

US08461310B2 Anti-ADAM-15 antibodies and utilization of the same 有权
标题翻译：抗ADAM-15抗体与利用相同
公开(公告)号：US08461310B2
公开(公告)日：2013-06-11
申请号：US12867449
申请日：2009-02-12
申请人： Toshimitsu Uede , Yutaka Matsui
发明人： Toshimitsu Uede , Yutaka Matsui
IPC分类号： C07K16/00
CPC分类号： C07K16/40 , A61K2039/505 , C07K14/8146 , C07K16/2842 , C07K16/2848 , C07K16/2896 , C07K2317/565 , C12N9/6416 , G01N2333/96486
摘要： A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin αvβ3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin αvβ1-dependent cell adhesion, and so on.
摘要翻译：从用于开发现有抗癌药物的观点来看，从不同观点获得的癌症治疗方法，即关注癌细胞的细胞间粘附。即，提供抑制癌细胞增殖和癌细胞的细胞间粘附的副作用较少的癌症的治疗方法。还提供了识别ADAM-15的去整合素结构域并可用作抗癌剂的抗体等。识别ADAM-15的整合素结构域但不识别ADAM-15的整合素结构域中的RGD序列或环区的抗体等等; 一种抗体，其抑制ADAM-15和整合素alphavbeta3依赖性细胞粘附等; 和抗体，其抑制ADAM-15和整合素α噬菌体依赖性细胞粘附等。

8. 发明授权

US10544466B2 Method for diagnosing and treating cancer brain metastasis and drug delivery system for enabling passage through blood-brain barrier 有权
公开(公告)号：US10544466B2
公开(公告)日：2020-01-28
申请号：US15552766
申请日：2015-02-24
申请人： GENE TECHNO SCIENCE CO., LTD. , NATIONAL CANCER CENTER , THEORIA Science Inc.
发明人： Takahiro Ochiya , Naoomi Tominaga
IPC分类号： C12N15/113 , A61P25/08 , A61P25/00 , A61P25/16 , A61P25/28 , C12Q1/6886 , A61P35/04
摘要： A method increases permeability of a blood-brain barrier in a subject. The method includes administering a small interfering ribonucleic acid (siRNA) against the 3-Phosphoinositide Dependent Protein Kinase 1 (PDPK1) gene or micro ribonucleic acid (miRNA) miR-181c as an active ingredient to the subject. The method can be applied for delivering a desired active agent to the subject.

9. 发明授权

US09040295B2 Anti-human α9 integrin antibody and use thereof 有权
标题翻译：抗人α9整联蛋白抗体及其用途
公开(公告)号：US09040295B2
公开(公告)日：2015-05-26
申请号：US13742680
申请日：2013-01-16
申请人： GENE TECHNO SCIENCE CO., LTD.
发明人： Shigeyuki Kon , Toshimitsu Uede
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28
CPC分类号： C07K16/2839 , C07K2317/76 , G01N2333/70546
摘要： The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin.
摘要翻译：本发明涉及抗人α9整联蛋白抗体。更具体地，本发明涉及：特异性识别人α9整联蛋白的单克隆抗体，嵌合抗体，人源化抗体和人抗体; 产生单克隆抗体的杂交瘤细胞; 生产单克隆抗体的方法; 用于产生杂交瘤细胞的方法; 包含抗人α9整联蛋白抗体的治疗剂; 包含人α9整联蛋白抗体的诊断剂; 以及筛选抑制人α9整联蛋白活性的化合物的方法。

10. 发明授权

US08901280B2 Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same 有权
标题翻译：细胞外基质蛋白氨基酸序列中的RGD抗体及其制备方法及用途
公开(公告)号：US08901280B2
公开(公告)日：2014-12-02
申请号：US12312022
申请日：2007-10-25
申请人： Shigeyuki Kon , Chiemi Kimura , Toshimitsu Uede
发明人： Shigeyuki Kon , Chiemi Kimura , Toshimitsu Uede
IPC分类号： C07K16/18 , A61K39/395 , C12N5/12 , C12N15/13 , A61P35/00 , A61P29/00 , A61P19/10 , A61P31/12 , C07K16/44 , G01N33/68 , G01N33/574 , A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/44 , C07K2317/34 , C07K2317/565 , C07K2317/76 , G01N33/574 , G01N33/6893 , G01N2800/102 , G01N2800/105 , G01N2800/108 , G01N2800/24 , G01N2800/26
摘要： The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.
摘要翻译：本发明提供了特异性识别人和小鼠的细胞外基质蛋白质的氨基酸序列中的RGD的单克隆抗体。通过特异性抑制RGD序列介导的粘附，可以同时预期对诸如炎症，癌症，感染性疾病，自身免疫性疾病和骨质疏松症以及不利影响的减少等有效影响。因此，可以为这些疾病提供更好的治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式